ANIX
Anixa Biosciences, Inc. [ANIX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ANIX Stock Summary
Top 10 Correlated ETFs
ANIX
Top 10 Correlated Stocks
ANIX
In the News
Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine
– Data to be released at approximately 6:00 p.m. ET, following presentation at 2023 SABCS – – Conference call to commence at 6:30 p.m.
FATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/Y
FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.
ANIXA BIOSCIENCES INC (ANIX) Upgraded to Buy: What Does It Mean for the Stock?
ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The 3 Most Undervalued Cheap Stocks to Buy in September 2023
The United States Treasury Secretary, Janet Yellen, recently expressed her confidence in the economy's ability to recover from the recession without causing significant harm to the job market or sparking excessive inflation. She believes that the United States will successfully navigate this economic challenge, maintaining control over consumer-price increases.This is leading to many investors considering cheap stocks to buy.
What Makes ANIXA BIOSCIENCES INC (ANIX) a New Buy Stock
ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?
Here is how ANIXA BIOSCIENCES INC (ANIX) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.
Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine
Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine
Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data
Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.
What Makes ANIXA BIOSCIENCES INC (ANIX) a Good Fit for "Trend Investing"
ANIXA BIOSCIENCES INC (ANIX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Anixa Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
SAN JOSE, Calif. , Aug. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C.
ANIX Financial details
ANIX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-10-31
| Metric | History | 2018-10-31 | 2019-10-31 | 2020-10-31 | 2021-10-31 | 2022-10-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.06 | 0.01 | 0 | 0.02 | 81.29 | |
| Net income per share | -0.79 | -0.61 | -0.46 | -0.45 | -0.44 | |
| Operating cash flow per share | -0.24 | -0.24 | -0.28 | -0.17 | -0.21 | |
| Free cash flow per share | -0.24 | -0.25 | -0.28 | -0.17 | -0.21 | |
| Cash per share | 0.29 | 0.3 | 0.41 | 1.25 | 0.98 | |
| Book value per share | 0.31 | 0.26 | 0.39 | 1.24 | 0.96 | |
| Tangible book value per share | 0.25 | 0.24 | 0.37 | 1.22 | 0.93 | |
| Share holders equity per share | 0.31 | 0.26 | 0.39 | 1.24 | 0.96 | |
| Interest debt per share | 0 | 0 | 0 | 0.01 | 0.01 | |
| Market cap | 71.38M | 76.59M | 45.79M | 145.47M | 170.09M | |
| Enterprise value | 68.32M | 73.09M | 39.43M | 116.6M | 157.96M | |
| P/E ratio | -5.1 | -6.39 | -4.52 | -11.24 | -12.61 | |
| Price to sales ratio | 64.16 | 306.35 | 0 | 283.84 | 0.07 | |
| POCF ratio | -16.7 | -16.15 | -7.41 | -29.47 | -26.2 | |
| PFCF ratio | -16.55 | -15.58 | -7.4 | -29.47 | -26.2 | |
| P/B Ratio | 13.13 | 14.63 | 5.23 | 4.1 | 5.86 | |
| PTB ratio | 13.13 | 14.63 | 5.23 | 4.1 | 5.86 | |
| EV to sales | 61.41 | 292.38 | 0 | 227.51 | 0.06 | |
| Enterprise value over EBITDA | -5.13 | -6.9 | -4.05 | -8.91 | -11.42 | |
| EV to operating cash flow | -15.99 | -15.42 | -6.38 | -23.62 | -24.33 | |
| EV to free cash flow | -15.85 | -14.87 | -6.37 | -23.62 | -24.33 | |
| Earnings yield | -0.2 | -0.16 | -0.22 | -0.09 | -0.08 | |
| Free cash flow yield | -0.06 | -0.06 | -0.14 | -0.03 | -0.04 | |
| Debt to equity | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | 0.23 | 0.33 | 0.65 | 2.21 | 0.88 | |
| Current ratio | 4.38 | 4.11 | 7.88 | 28.34 | 14.83 | |
| Interest coverage | 0 | 0 | 0 | 0 | -133.41 | |
| Income quality | 0.3 | 0.4 | 0.61 | 0.38 | 0.47 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 6.21 | 22.65 | 0 | 13.8 | 0 | |
| Research and developement to revenue | 6.12 | 21.89 | 0 | 12.08 | 0 | |
| Intangibles to total assets | 0.13 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.04 | 0 | 0 | 0 | |
| Capex to revenue | -0.03 | -0.7 | 0 | 0 | 0 | |
| Capex to depreciation | -0.11 | -0.38 | -0.18 | 0 | 0 | |
| Stock based compensation to revenue | 8 | 22.85 | 0 | 15.72 | 0 | |
| Graham number | 2.35 | 1.9 | 2.01 | 3.56 | 3.09 | |
| ROIC | -2.69 | -2.22 | -1.13 | -0.36 | -0.46 | |
| Return on tangible assets | -2.49 | -1.91 | -1.07 | -0.36 | -0.44 | |
| Graham Net | 0.22 | 0.16 | 0.29 | 1.2 | 0.9 | |
| Working capital | 4.27M | 4.61M | 8.18M | 34.73M | 28.16M | |
| Tangible asset value | 4.35M | 4.81M | 8.26M | 34.77M | 28.2M | |
| Net current asset value | 4.27M | 4.61M | 8.18M | 34.51M | 27.99M | |
| Invested capital | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 0 | 33.26K | 34.38K | 1.12K | 0 | |
| Average payables | 531.17K | 583.91K | 409.09K | 184.28K | 200.6K | |
| Average inventory | 0 | -1.18M | -2.5M | -1.32M | 0 | |
| Days sales outstanding | 0 | 97.13 | 0 | 0 | 0 | |
| Days payables outstanding | 276.46 | 1.29K | 0 | 129.12 | 0 | |
| Days of inventory on hand | 0 | -5.16K | 0 | 0 | 0 | |
| Receivables turnover | 0 | 3.76 | 0 | 0 | 0 | |
| Payables turnover | 1.32 | 0.28 | 0 | 2.83 | 0 | |
| Inventory turnover | 0 | -0.07 | 0 | 0 | 0 | |
| ROE | -2.58 | -2.29 | -1.16 | -0.37 | -0.46 | |
| Capex per share | 0 | -0.01 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-07-31 for Q3
| Metric | History | 2022-07-31 | 2022-10-31 | 2023-01-31 | 2023-04-30 | 2023-07-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 81.29 | 0 | 0.01 | 0 | |
| Net income per share | -0.09 | -0.11 | -0.07 | -0.07 | -0.08 | |
| Operating cash flow per share | -0.05 | -0.05 | -0.06 | -0.03 | -0.05 | |
| Free cash flow per share | -0.05 | -0.05 | -0.06 | -0.03 | -0.05 | |
| Cash per share | 1.04 | 0.98 | 0.9 | 0.87 | 0.82 | |
| Book value per share | 1.04 | 0.96 | 0.9 | 0.87 | 0.82 | |
| Tangible book value per share | 1.01 | 0.93 | 0.87 | 0.84 | 0.79 | |
| Share holders equity per share | 1.04 | 0.96 | 0.9 | 0.87 | 0.82 | |
| Interest debt per share | 0.01 | 0.01 | 0.01 | 0 | 0.01 | |
| Market cap | 118.15M | 170.09M | 135.12M | 123.72M | 111.2M | |
| Enterprise value | 94.13M | 157.96M | 125.54M | 118.3M | 108.19M | |
| P/E ratio | -10.93 | -12.52 | -15.93 | -15.2 | -11.07 | |
| Price to sales ratio | 0 | 0.07 | 0 | 589.14 | 0 | |
| POCF ratio | -84.63 | -106.78 | -67.97 | -153.31 | -76.95 | |
| PFCF ratio | -84.63 | -106.78 | -67.97 | -153.31 | -76.95 | |
| P/B Ratio | 3.73 | 5.86 | 4.86 | 4.61 | 4.36 | |
| PTB ratio | 3.73 | 5.86 | 4.86 | 4.61 | 4.36 | |
| EV to sales | 0 | 0.06 | 0 | 563.32 | 0 | |
| Enterprise value over EBITDA | -33.77 | -43.9 | -49.33 | -46.43 | -38.19 | |
| EV to operating cash flow | -67.43 | -99.16 | -63.15 | -146.59 | -74.87 | |
| EV to free cash flow | -67.43 | -99.16 | -63.15 | -146.59 | -74.87 | |
| Earnings yield | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | |
| Free cash flow yield | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | 8.62 | 3.37 | 3.76 | 2.13 | 1.06 | |
| Current ratio | 22.01 | 14.83 | 22.81 | 17.83 | 14.22 | |
| Interest coverage | -127.14 | -45.11 | -12.65 | 10.12 | 0 | |
| Income quality | 0.5 | 0.45 | 0.84 | 0.35 | 0.57 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 7.67 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 4.75 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 5.72 | 0 | |
| Graham number | 1.44 | 1.55 | 1.18 | 1.13 | 1.23 | |
| ROIC | -0.08 | -0.12 | -0.08 | -0.08 | -0.11 | |
| Return on tangible assets | -0.08 | -0.11 | -0.07 | -0.07 | -0.09 | |
| Graham Net | 0.99 | 0.9 | 0.85 | 0.82 | 0.77 | |
| Working capital | 30.87M | 28.16M | 26.87M | 25.87M | 24.54M | |
| Tangible asset value | 30.91M | 28.2M | 26.91M | 25.91M | 24.59M | |
| Net current asset value | 30.68M | 27.99M | 26.71M | 25.72M | 24.41M | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 0 | 0 | 73.5K | 201.5K | 295K | |
| Average payables | 160K | 246K | 187.5K | 152.5K | 144.5K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 109.71 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 109.01 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0.82 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0.83 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.09 | -0.12 | -0.08 | -0.08 | -0.1 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ANIX Frequently Asked Questions
What is Anixa Biosciences, Inc. stock symbol ?
Anixa Biosciences, Inc. is a US stock , located in San jose of Ca and trading under the symbol ANIX
Is Anixa Biosciences, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $8. The lowest prediction is $8 and the highest is $8
What is ANIX stock prediction ?
What is Anixa Biosciences, Inc. stock quote today ?
Anixa Biosciences, Inc. stock price is $4.1798 today.
Is Anixa Biosciences, Inc. stock public?
Yes, Anixa Biosciences, Inc. is a publicly traded company.
Company Profile
- Volume Average 93.56K
- Market Capitalization 126.77M
- Employee 4
- CEO Dr. Amit Kumar Ph.D.
- Headquarters San Jose,CA,US
- IPO Date 1983-10-07
-
Website
https://www.anixa.com 
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
